Prostate cancer is the most common noncutaneous cancer among men, rendering the diagnosis and staging of significant medical and public interest. One of the most interesting developments in the application of nuclear oncology has been the development of novel diagnostic agents that are able to facilitate targeted therapies using the concept of theranostics. This review summarizes the current and emerging molecular imaging techniques for the investigation of patients with prostate cancer with emphasis on the potential of 64Cu-PSMA PET/CT in staging, restaging, and the application of theranostics.
PET clinics. 2017 Jan 31 [Epub]
Aviral Singh, Harshad R Kulkarni, Richard P Baum
THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka 99437, Germany. Electronic address: ., THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, Bad Berka 99437, Germany.